Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zunsemetinib versus placebo in moderate-to-severe active psoriatic arthritis
2022-000847-62Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Zunsemetinib with Placebo (2 arms). Primary endpoint: ACR20 at Week 12. Started Aug 2022; status: completed.
02
Drugs
zunsemetinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2022-000847-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000847-62.